Nystatin-intralipid preparation: Characterization and in vitro activity against yeasts and molds

Mycopathologia

Volumn 169, Issue 5, 2010, Pages 333-341

  Semis, R ^a   Polacheck, I ^b   Segal, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Aspergillus; Candida; In vitro susceptibility; Nystatin intralipid

Indexed keywords

ANTIFUNGAL AGENT; LIPID EMULSION; NYSTATIN;

ANIMAL; ARTICLE; ASPERGILLUS; CANDIDA; CHEMISTRY; DIET SUPPLEMENTATION; DRUG EFFECT; ERYTHROCYTE; FUSARIUM; HUMAN; MICROBIOLOGICAL EXAMINATION; SHEEP;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DIETARY SUPPLEMENTS; ERYTHROCYTES; FAT EMULSIONS, INTRAVENOUS; FUSARIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; NYSTATIN; SHEEP;

ASPERGILLUS; CANDIDA; FUSARIUM; OVIS ARIES;

EID: 77952675330     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-009-9271-z     Document Type: Article

References (29)

1. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007; 45: 321-46.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39: 309-17.
3. Kauffman CA. Fungal infections. Proc Am Thorac Soc. 2006; 3: 35-40.
4. Richardson MD, Warnock DW. Antifungal drugs. In: Fungal infection. Diagnosis and management. Blackwell; 2000. p. 29-79.
5. Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin. 2007; 25: 165-83.
6. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006; 27(Suppl 1): 12-6.
7. Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharmaceut Sci. 2003; 6: 67-83.
8. Shadkhan Y, Segal E, Bor A, Gov Y, Rubin M, Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother. 1997; 39: 655-8.
9. Sionov E, Segal E. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures. Med Mycol. 2004; 42: 73-80.
10. Sionov E, Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol. 2003; 39: 221-7.
11. Shadkchan Y, Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother. 1999; 44: 787-90.
12. Shadkchan Y, Segal E. Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice. J Antimicrob Chemother. 2001; 48: 245-51.
13. Shadkchan Y, Zaslavsky Z, Segal E. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid. Med Mycol. 2003; 41: 15-9.
14. Shadkchan Y, Keisari Y, Segal E. Cytokines in mice treated with amphotericin B-intralipid. Med Mycol. 2004; 42: 123-8.
15. Moreau P, Milpied N, Fayette N, Ramée JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992; 30: 535-41.
16. Washington C, Lance M, Davis SS. Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother. 1993; 31: 806-8.
17. Chavanet P, Clement C, Duong M, Buisson M, D'Athis P, Dumas M, et al. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate-fat emulsion in HIV-infected patients with oral candidosis. Clin Microbiol Infect. 1997; 3: 455-61.
18. National Committee for Clinical Laboratory Standarts. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Wayne, PA, USA, 1997.
19. National Committee for Clinical Laboratory Standarts. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. NCCLS, Wayne, PA, USA, 1997.
20. Souza LC, Maranhao RC, Schreier S, Campa A. In vitro and in vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother. 1993; 32: 123-32.
21. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol. 2005; 131: 201-7.
22. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004; 101: 1594-600.
23. Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol. 2005; 20: 349-53.
24. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, et al. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002; 40: 1406-12.
25. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother. 1999; 43: 1264-6.
26. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998; 42: 1412-6.
27. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999; 37: 2343-5.
28. Ledbetter EC, Patten VH, Scarlett JM, Vermeylen FM. In vitro susceptibility patterns of fungi associated with keratomycosis in horses of the northeastern United States: 68 cases (1987-2006). J Am Vet Med Assoc. 2007; 231: 1086-91.
29. Tzatzarakis MN, Tsatsakis AM, Charvalos E, Vakalounakis D. Comparison of in vitro activities, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. J Environ Sci Health. 2001; 36: 331-40.